Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer's Vitrakvi On Track To Become EU’s First Tumor-Agnostic Cancer Treatment

Executive Summary

Five new medicines, including what could become Europe’s first ever tumor-agnostic cancer treatment, have been recommended for approval by the European Medicines Agency.

You may also be interested in...



Third Time Lucky for Roche’s Polivy in Europe?

It’s decision time again at the European Medicines Agency and Roche’s Polivy is one of the new drug applications that is up for a potential marketing recommendation.

Second Chance For Roche’s Polivy At CHMP

It's decision time again at the European Medicines Agency and Roche's Polivy and AstraZeneca's Qternmet are among the products up for an opinion on whether they should be approved in the EU.

Tecentriq Takes EU Lead In Triple-Negative Breast Cancer

Roche’s checkpoint inhibitor has been approved in combination with nab-paclitaxel in the EU for triple-negative breast cancer, cementing the company’s role as an innovator in breast cancer therapies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS140576

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel